In this randomized clinical trial including 106 patients, combining atezolizumab with carboplatin significantly improved progression-free and overall survival of patients with metastatic TNBC; tumor-infiltrating lymphocytes, mutation burden, obesity, and increased blood glucose levels were associated with response to anti–programmed cell death ligand 1 therapy. This evidence concerns the gene CD274 and Obesity.